Search research articles
Contact Us
Filters
Showing results (31-40 of 46) with videos related to
Page
of 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 28, 2010
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer
Ian E Krop, Muralidhar Beeram, Shanu Modi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2009
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
Sharmila Makhija, Lukas C Amler, Dana Glenn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2009
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab
Evelyn Yao, Wei Zhou, Si Tuen Lee-Hoeflich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)
Hirdesh Uppal, Estelle Doudement, Kaushiki Mahapatra, et al.
Cancer Research
|
October 20, 2017
Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates
Niña G Caculitan, Josefa Dela Cruz Chuh, Yong Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy
Gail D Lewis Phillips, Carter T Fields, Guangmin Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2010
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer
Jagath R Junutula, Kelly M Flagella, Richard A Graham, et al.
Cancer Research
|
November 18, 2008
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
Gail D Lewis Phillips, Guangmin Li, Debra L Dugger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2012
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients
Sara A Hurvitz, David J Betting, Howard M Stern, et al.
Cancer Discovery
|
May 16, 2012
PPM1H is a p27 phosphatase implicated in trastuzumab resistance
Si Tuen Lee-Hoeflich, Thinh Q Pham, Don Dowbenko, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 46) with videos related to
Sort By:
Page
of 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 28, 2010
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer
Ian E Krop, Muralidhar Beeram, Shanu Modi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2009
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
Sharmila Makhija, Lukas C Amler, Dana Glenn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2009
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab
Evelyn Yao, Wei Zhou, Si Tuen Lee-Hoeflich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2014
Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)
Hirdesh Uppal, Estelle Doudement, Kaushiki Mahapatra, et al.
Cancer Research
|
October 20, 2017
Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates
Niña G Caculitan, Josefa Dela Cruz Chuh, Yong Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 8, 2013
Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy
Gail D Lewis Phillips, Carter T Fields, Guangmin Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2010
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer
Jagath R Junutula, Kelly M Flagella, Richard A Graham, et al.
Cancer Research
|
November 18, 2008
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
Gail D Lewis Phillips, Guangmin Li, Debra L Dugger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2012
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients
Sara A Hurvitz, David J Betting, Howard M Stern, et al.
Cancer Discovery
|
May 16, 2012
PPM1H is a p27 phosphatase implicated in trastuzumab resistance
Si Tuen Lee-Hoeflich, Thinh Q Pham, Don Dowbenko, et al.
Page
of 5